William Blair analyst Myles Minter has maintained their bullish stance on ARGX stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Myles Minter has given his Buy rating due to a combination of factors surrounding Argenx Se’s stock. Despite recent volatility in Argenx shares following an FDA safety report, Minter views the situation as a buying opportunity. The report highlighted potential safety concerns with Vyvgart Hytrulo, but these are not new findings, and Argenx is proactively addressing them through clinician education and ongoing studies.
Furthermore, Minter points out that the real-world data shows a significantly lower rate of disease worsening in CIDP patients treated with Vyvgart Hytrulo compared to earlier reports. This, combined with the anticipated results from a Phase IV switch study, suggests that the risks are being effectively managed. Minter believes that as more clinical data emerges and clinician familiarity with the treatment increases, the stock’s potential will be further realized.
In another report released today, Bank of America Securities also maintained a Buy rating on the stock with a $804.00 price target.